Cargando…
Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension
BACKGROUND: Impaired actin–myosin cross-bridge (CB) dynamics correlate with impaired left ventricular (LV) function in early diabetic cardiomyopathy (DCM). Elevated expression and activity of Rho kinase (ROCK) contributes to the development of DCM. ROCK targets several sarcomeric proteins including...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509700/ https://www.ncbi.nlm.nih.gov/pubmed/26194354 http://dx.doi.org/10.1186/s12933-015-0256-6 |
_version_ | 1782382067781206016 |
---|---|
author | Waddingham, Mark T Edgley, Amanda J Astolfo, Alberto Inagaki, Tadakatsu Fujii, Yutaka Du, Cheng-Kun Zhan, Dong-Yun Tsuchimochi, Hirotsugu Yagi, Naoto Kelly, Darren J Shirai, Mikiyasu Pearson, James T |
author_facet | Waddingham, Mark T Edgley, Amanda J Astolfo, Alberto Inagaki, Tadakatsu Fujii, Yutaka Du, Cheng-Kun Zhan, Dong-Yun Tsuchimochi, Hirotsugu Yagi, Naoto Kelly, Darren J Shirai, Mikiyasu Pearson, James T |
author_sort | Waddingham, Mark T |
collection | PubMed |
description | BACKGROUND: Impaired actin–myosin cross-bridge (CB) dynamics correlate with impaired left ventricular (LV) function in early diabetic cardiomyopathy (DCM). Elevated expression and activity of Rho kinase (ROCK) contributes to the development of DCM. ROCK targets several sarcomeric proteins including myosin light chain 2, myosin binding protein-C (MyBP-C), troponin I (TnI) and troponin T that all have important roles in regulating CB dynamics and contractility of the myocardium. Our aim was to examine if chronic ROCK inhibition prevents impaired CB dynamics and LV dysfunction in a rat model of early diabetes, and whether these changes are associated with changes in myofilament phosphorylation state. METHODS: Seven days post-diabetes induction (65 mg/kg ip, streptozotocin), diabetic rats received the ROCK inhibitor, fasudil (10 mg/kg/day ip) or vehicle for 14 days. Rats underwent cardiac catheterization to assess LV function simultaneous with X-ray diffraction using synchrotron radiation to assess in situ CB dynamics. RESULTS: Compared to controls, diabetic rats developed mild systolic and diastolic dysfunction, which was attenuated by fasudil. End-diastolic and systolic myosin proximity to actin filaments were significantly reduced in diabetic rats (P < 0.05). In all rats there was an inverse correlation between ROCK1 expression and the extension of myosin CB in diastole, with the lowest ROCK expression in control and fasudil-treated diabetic rats. In diabetic and fasudil-treated diabetic rats changes in relative phosphorylation of TnI and MyBP-C were not significant from controls. CONCLUSIONS: Our results demonstrate a clear role for ROCK in the development of LV dysfunction and impaired CB dynamics in early DCM. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-015-0256-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4509700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45097002015-07-22 Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension Waddingham, Mark T Edgley, Amanda J Astolfo, Alberto Inagaki, Tadakatsu Fujii, Yutaka Du, Cheng-Kun Zhan, Dong-Yun Tsuchimochi, Hirotsugu Yagi, Naoto Kelly, Darren J Shirai, Mikiyasu Pearson, James T Cardiovasc Diabetol Original Investigation BACKGROUND: Impaired actin–myosin cross-bridge (CB) dynamics correlate with impaired left ventricular (LV) function in early diabetic cardiomyopathy (DCM). Elevated expression and activity of Rho kinase (ROCK) contributes to the development of DCM. ROCK targets several sarcomeric proteins including myosin light chain 2, myosin binding protein-C (MyBP-C), troponin I (TnI) and troponin T that all have important roles in regulating CB dynamics and contractility of the myocardium. Our aim was to examine if chronic ROCK inhibition prevents impaired CB dynamics and LV dysfunction in a rat model of early diabetes, and whether these changes are associated with changes in myofilament phosphorylation state. METHODS: Seven days post-diabetes induction (65 mg/kg ip, streptozotocin), diabetic rats received the ROCK inhibitor, fasudil (10 mg/kg/day ip) or vehicle for 14 days. Rats underwent cardiac catheterization to assess LV function simultaneous with X-ray diffraction using synchrotron radiation to assess in situ CB dynamics. RESULTS: Compared to controls, diabetic rats developed mild systolic and diastolic dysfunction, which was attenuated by fasudil. End-diastolic and systolic myosin proximity to actin filaments were significantly reduced in diabetic rats (P < 0.05). In all rats there was an inverse correlation between ROCK1 expression and the extension of myosin CB in diastole, with the lowest ROCK expression in control and fasudil-treated diabetic rats. In diabetic and fasudil-treated diabetic rats changes in relative phosphorylation of TnI and MyBP-C were not significant from controls. CONCLUSIONS: Our results demonstrate a clear role for ROCK in the development of LV dysfunction and impaired CB dynamics in early DCM. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-015-0256-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-22 /pmc/articles/PMC4509700/ /pubmed/26194354 http://dx.doi.org/10.1186/s12933-015-0256-6 Text en © Waddingham et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Original Investigation Waddingham, Mark T Edgley, Amanda J Astolfo, Alberto Inagaki, Tadakatsu Fujii, Yutaka Du, Cheng-Kun Zhan, Dong-Yun Tsuchimochi, Hirotsugu Yagi, Naoto Kelly, Darren J Shirai, Mikiyasu Pearson, James T Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension |
title | Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension |
title_full | Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension |
title_fullStr | Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension |
title_full_unstemmed | Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension |
title_short | Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension |
title_sort | chronic rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509700/ https://www.ncbi.nlm.nih.gov/pubmed/26194354 http://dx.doi.org/10.1186/s12933-015-0256-6 |
work_keys_str_mv | AT waddinghammarkt chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension AT edgleyamandaj chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension AT astolfoalberto chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension AT inagakitadakatsu chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension AT fujiiyutaka chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension AT duchengkun chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension AT zhandongyun chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension AT tsuchimochihirotsugu chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension AT yaginaoto chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension AT kellydarrenj chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension AT shiraimikiyasu chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension AT pearsonjamest chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension |